Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)

NCT04943627 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT04943627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04943627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)
Lead sponsor
Agenus Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
August 2, 2021
Completion date
October 22, 2021
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cervical cancer